Speak with me

Recent changes.

Catalyst dates move. This page lists every date on the biotech catalyst calendar that has changed in the last 30 days, and every row withdrawn in that period, with the date it moved from. A row that moves keeps its identity, so a calendar subscription updates the event in place rather than adding a second one. Nothing is ever deleted quietly.

Last compiled .

WasNowLaneCompanyEventSource
1 Sept 2026ClinicalGilead SciencesAs of 11 September 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in March 2027.NCT05186974
1 Oct 2026ClinicalRetension Pharmaceuticals. Inc.As of 10 September 2026, Retension Pharmaceuticals. estimated primary completion of a Phase 2 trial in Uncontrolled Hypertension, in March 2027.NCT07142356
31 Oct 2026ClinicalHoffmann-La RocheAs of 10 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Breast Cancer, on 19 October 2026.NCT05852691
1 Jan 2027ClinicalMerz Aesthetics GmbHAs of 10 September 2026, Merz Aesthetics estimated primary completion of a Phase 3 trial in Neuromuscular Agents, in October 2026.NCT07210463
22 Jan 2027ClinicalGlaxoSmithKlineAs of 9 September 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in asthma, on 26 January 2027.NCT05757102
14 Dec 2026ClinicalNovo Nordisk A/SAs of 9 September 2026, Novo Nordisk estimated primary completion of a Phase 3 trial in Cardiovascular Risk, on 29 January 2027.NCT06118281
31 Aug 2026ClinicalSuzhou Suncadia Biopharmaceuticals Co., Ltd.As of 8 September 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in nSCLC, in December 2026.NCT06844474
11 Dec 2026ClinicalGlaxoSmithKlineAs of 8 September 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 23 November 2026.NCT07596199
26 Aug 2026ClinicalHoffmann-La RocheAs of 4 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 18 November 2026.NCT06450639
1 Dec 2026ClinicalAspeya, Inc.As of 2 September 2026, Aspeya estimated primary completion of a Phase 2 trial in migraine, in March 2027.NCT07646613
30 Nov 2026ClinicalCartesian TherapeuticsAs of 1 September 2026, Cartesian Therapeutics estimated primary completion of a Phase 3 trial in Myasthaenia Gravis, on 30 December 2026.NCT06799247
15 Oct 2026ClinicalAstraZenecaAs of 1 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in RSV Respiratory Syncytial Virus, on 7 October 2026.NCT07717840
11 Nov 2026ClinicalJanssen Research & Development, LLCAs of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Ischemic Stroke; Ischemic Attack, Transient, on 15 October 2026.NCT05702034
31 Oct 2026ClinicalJanssen Research & Development, LLCAs of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Atrial Fibrillation, on 8 December 2026.NCT05757869
18 Sept 2026ClinicalTakedaAs of 27 August 2026, Takeda estimated primary completion of a Phase 2 trial in Crohn's Disease, on 17 February 2027.NCT06233461
31 Aug 2026ClinicalUCB Biopharma SRLAs of 11 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 30 September 2026.NCT05077904
22 Sept 2026ClinicalMerck Sharp & Dohme LLCAs of 20 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 October 2026.NCT05468697
30 Aug 2026ClinicalReCode TherapeuticsAs of 19 August 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, in November 2026.NCT06237335
14 Oct 2026ClinicalGlaxoSmithKlineAs of 17 August 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 16 September 2026.NCT07596173
30 Nov 2026ClinicalMirati Therapeutics Inc.As of 14 August 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced Cancer, on 30 October 2026.NCT05853575